Ellie He

540 total citations
21 papers, 405 citations indexed

About

Ellie He is a scholar working on Physiology, Anesthesiology and Pain Medicine and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Ellie He has authored 21 papers receiving a total of 405 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Physiology, 9 papers in Anesthesiology and Pain Medicine and 8 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Ellie He's work include Pain Mechanisms and Treatments (11 papers), Pain Management and Opioid Use (9 papers) and Opioid Use Disorder Treatment (8 papers). Ellie He is often cited by papers focused on Pain Mechanisms and Treatments (11 papers), Pain Management and Opioid Use (9 papers) and Opioid Use Disorder Treatment (8 papers). Ellie He collaborates with scholars based in United States, United Kingdom and Switzerland. Ellie He's co-authors include David E. Geller, Gerhild Angyalosi, Mark Higgins, Matthias Kappler, R. Chiron, Florian Brockhaus, Patrick A. Flume, Michael W. Konstan, Jie Zhang and Warren Wen and has published in prestigious journals such as Journal of Clinical Investigation, British Journal of Clinical Pharmacology and Clinical Therapeutics.

In The Last Decade

Ellie He

18 papers receiving 388 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ellie He United States	8	283	102	82	66	65	21	405
Antonio Salcedo Spain	10	295 1.0×	85 0.8×	101 1.2×	5 0.1×	33 0.5×	19	403
Christina Hamacher Germany	11	302 1.1×	123 1.2×	52 0.6×	9 0.1×	16 0.2×	11	546
Bo Tomas Brofeldt United States	7	80 0.3×	49 0.5×	87 1.1×	66 1.0×	132 2.0×	11	424
Maria Anastasaki Greece	11	119 0.4×	30 0.3×	47 0.6×	27 0.4×	8 0.1×	14	354
J. Marey López Spain	8	28 0.1×	30 0.3×	211 2.6×	131 2.0×	17 0.3×	21	826
G. Molter Germany	13	31 0.1×	25 0.2×	61 0.7×	10 0.2×	163 2.5×	28	387
Hisako Arai Japan	6	80 0.3×	103 1.0×	38 0.5×	8 0.1×	6 0.1×	10	557
Ti Yin Taiwan	14	68 0.2×	13 0.1×	49 0.6×	17 0.3×	10 0.2×	27	509
E. Samsó Spain	11	19 0.1×	30 0.3×	72 0.9×	9 0.1×	66 1.0×	21	311

Countries citing papers authored by Ellie He

Since Specialization

Citations

This map shows the geographic impact of Ellie He's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellie He with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellie He more than expected).

Fields of papers citing papers by Ellie He

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ellie He. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellie He. The network helps show where Ellie He may publish in the future.

Co-authorship network of co-authors of Ellie He

This figure shows the co-authorship network connecting the top 25 collaborators of Ellie He. A scholar is included among the top collaborators of Ellie He based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ellie He. Ellie He is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cipriano, Alessandra, Ellie He, Manjunath S. Shet, Glen Apseloff, & Stephen Harris. (2025). Reversal of Fentanyl‐Induced Respiratory Depression in Healthy Subjects by Intramuscular Nalmefene Administered by Auto‐Injector Versus Intranasal Naloxone. The Journal of Clinical Pharmacology. 65(12). 1661–1675.

Whiteside, Garth T., et al.. (2025). Efficacy and safety of a selective partial agonist for nociception/orphanin‐FQ peptide (NOP) receptors in patients with insomnia disorder. British Journal of Clinical Pharmacology. 92(1). 172–185.

Cipriano, Alessandra, Glen Apseloff, Ram P. Kapil, et al.. (2024). Time Course of Reversal of Fentanyl‐Induced Respiratory Depression in Healthy Subjects by Intramuscular Nalmefene and Intramuscular and Intranasal Naloxone. The Journal of Clinical Pharmacology. 65(2). 206–216. 2 indexed citations

Whiteside, Garth T., Donald J. Kyle, Ram P. Kapil, et al.. (2023). The nociceptin/orphanin FQ receptor partial agonist sunobinop promotes non-REM sleep in rodents and patients with insomnia. Journal of Clinical Investigation. 134(1). 7 indexed citations

Weiss, Margaret D., Craig Surman, Atul Khullar, et al.. (2021). Effect of a Multilayer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adolescents with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Fixed-Dose, Placebo-Controlled Trial Followed by a 6-Month Open-Label Follow-Up. Journal of Child and Adolescent Psychopharmacology. 31(9). 623–630. 7 indexed citations

Weiss, Margaret D., et al.. (2021). Effect of a Multi-Layer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adults with ADHD: A Randomized, Double-Blind, Forced-Dose, Placebo-Controlled Trial Followed by a 6-month Open-Label Extension. CNS Drugs. 35(6). 667–679. 6 indexed citations

He, Ellie. (2017). Evaluation of the Ototoxicity Potential of OnceDaily, Single-Entity Hydrocodone in Patientswith Chronic Pain: Results of Two Phase-3Clinical Studies. Pain Physician. 1(21;1). E183–E193. 6 indexed citations

Pergolizzi, Joseph V., et al.. (2017). Effectiveness and Safety of Once-Daily Extended-Release Hydrocodone in Individuals Previously Receiving Immediate-Release Oxycodone for Chronic Pain. Pain Medicine. 19(5). 967–977. 3 indexed citations

He, Ellie, et al.. (2017). Safety and Effectiveness of Once-Daily Hysingla Extended-Release Tablets in Patients with Baseline Depression or Anxiety. Pain Management. 7(6). 473–488. 1 indexed citations

10.

Pergolizzi, Joseph V., et al.. (2016). Long-term effectiveness and safety of once-daily, single-entity, extended-release hydrocodone in patients of ≥75 years of age with moderate to severe nonmalignant and nonneuropathic pain. Geriatric Nursing. 38(1). 39–47. 5 indexed citations

11.

Pergolizzi, Joseph V., et al.. (2016). Efficacy and Safety of Once‐Daily Extended‐Release (ER) Hydrocodone in Individuals Previously Receiving ER Morphine for Chronic Pain. Pain Practice. 17(3). 382–391. 2 indexed citations

12.

He, Ellie, et al.. (2016). Hysingla® ER, a once-daily, single-entity hydrocodone with abuse-deterrent properties in treating chronic nonmalignant and nonneuropathic pain in patients with osteoarthritis. Postgraduate Medicine. 129(1). 133–139. 3 indexed citations

13.

Wen, Warren, et al.. (2015). A multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of single-entity, once-daily hydrocodone tablets in patients with uncontrolled moderate to severe chronic low back pain. Expert Opinion on Pharmacotherapy. 16(11). 1593–1606. 28 indexed citations

14.

Kapil, Ram P., Alessandra Cipriano, Warren Wen, et al.. (2015). Pharmacokinetic Profile and Sustained 24-hour Analgesia of a Once-daily Hydrocodone Bitartrate Extended-release Tablet with Abuse-deterrent Properties. Clinical Therapeutics. 38(2). 302–314. 4 indexed citations

15.

Wen, Warren, et al.. (2015). 12-Month safety and effectiveness of once-daily hydrocodone. Journal of Opioid Management. 11(4). 339–356. 18 indexed citations

16.

He, Ellie, et al.. (2015). Long-term safety and effectiveness of once-daily, single-entity, extended-release hydrocodone over 76 weeks of an open-label study in patients with chronic noncancer and nonneuropathic pain. Postgraduate Medicine. 128(1). 23–33. 6 indexed citations

17.

Michna, Edward, et al.. (2014). Efficacy and safety of once-daily, extended-release hydrocodone in individuals previously receiving hydrocodone/acetaminophen combination therapy for chronic pain. Postgraduate Medicine. 127(1). 5–12. 10 indexed citations

18.

Geller, David E., Samya Z. Nasr, Simon Piggott, et al.. (2013). Tobramycin Inhalation Powder in Cystic Fibrosis Patients: Response by Age Group. Respiratory Care. 59(3). 388–398. 33 indexed citations

19.

Banerji, Donald, et al.. (2012). Once-daily NVA237 reduces exacerbations and improves symptoms in COPD patients: A pooled analysis of the GLOW1 and GLOW2 studies. 40. 2885. 1 indexed citations

20.

Konstan, Michael W., Patrick A. Flume, Matthias Kappler, et al.. (2010). Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. Journal of Cystic Fibrosis. 10(1). 54–61. 255 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact